ALL chemotherapy protocol

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76

Hispanic patients aged 10 years and older treated for ALL on DFCI 05-001 had a significantly lower cumulative incidence of osteonecrosis compared to non-Hispanic patients, remaining significant in mul

Effect: improvement; HR 0.28; CI: 95% CI 0.10-0.76